TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Microembolism in the Critically Ill With Acute Kidney Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \> 18 yrs.~* Signed IC~Exclusion Criteria:~* Heart disease (PFO, ASD, VSD, severe valvular disease)~* Atrial fibrillation~* Cerebrovascular pathology~* Missing temporal bone window~* Allergy to plastic contained in the investigative device (transcranial Doppler)~* Chronic kidney disease~* Pregnancy~* Participation in another study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRRT group (Type: ACTIVE_COMPARATOR): the CRRT group receives continuous renal replacement therapy for acute kidney injury
- IRRT group (Type: ACTIVE_COMPARATOR): the IRRT group receives intermittent renal replacement therapy after termination of CRRT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Diagnosis of Muscular Weakness Syndrome After a Stay in Intensive Care : Measurement by Ultrasound

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Predictable mechanical ventilation time of at least 48 hours~* Patient intubated for less than 48 hours~* Social security~* Not opposing, or whose family does not object to this research~Exclusion Criteria:~* Neuromuscular pathology~* Amputation of one of the limbs~* Central or peripheral neurological impairment impacting the realization of the MRC score~* Orthopaedic trauma of the limbs or the pelvis preventing the achievement of an MRC score at the exit of resuscitation or by default at J28~* Subject in exclusion period of another study~* Persons referred to in Articles L1121-5 to L1121-8 of the CSP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Direct Current Stimulation, Improve Functional Motor Recovery, Affected Arm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Unilateral, 1st acute stroke event within 4 weeks of admission to an in-patient rehabilitation facility~2. Ischemic stroke documented clinically and by neuroimaging.~3. Severe upper limb weakness (MRC grade of 2 or less at the shoulder joint)~4. Medically stable from a cardio-respiratory stand point so that they can participate in daily therapies.~5. Depressed patients will be included in the study (psychiatrist referral will be made if deemed necessary).~6. Aphasic alert patients will be included in the study provided they were able to follow simple directions by verbal or gestural cues and provided with a written informed consent.~7. Informed consent, from cognitively intact patients (admission Mini Mental Scale Examination \[MMSE\] greater than or equal to 21). When it is not possible for the patient to provide informed consent or patient is cognitively impaired with MMSE ≤ 20, proxy consent will be obtained from the next of kin (legal authorized representative) according to institutional IRB standards. Informed consent will be obtained by the admitting physicians.~Exclusion Criteria:~1. Hemorrhagic strokes~2. Patient's with an episode post-stroke seizure or history of epilepsy.~3. Patients medically unstable, demented, or terminally ill (e.g., patients with stroke as a complication of a terminal cancer).~4. On medications such as botox for spasticity or other medications known to enhance motor recovery such as d-amphetamine,~5. Stroke patients with implanted pacemakers and defibrillators.~6. Refusal to provide informed consent

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- t DC stimulation (Type: SHAM_COMPARATOR): Sham transcranial direct current stimulation tDCS induces slight short-lasting tingling with onset of the stimulation. These sensations usually fade away in seconds. Sham interventions are essential to blind the subject and the assessor in order to obtain unbiased assessment of intervention effects
- tDC stimulation (Type: EXPERIMENTAL): Actual DC stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Improved Implant for Reconstruction Purposes After Mandibular Resection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years at time of study entry.~* T4 oral cavity tumor with mandible invasion, requiring segmental mandibulectomy.~* Reconstruction with free fibula flap not feasible because of any or a combination of the following reasons:~oCT angiography of the legs and/or the neck shows severe stenosis of the ves-sels.~* Previous medical history of severe atherosclerotic disease.~* General health condition necessitating a shorter operation time.~  * Cases will be discussed in the multidisciplinary tumor board that they are eligible for composite resection but not eligible for free fibula flap.~ * Written informed consent.~Exclusion Criteria:~* Patients who are eligible for free fibula flap.~* Pregnancy.~* General health condition does not allow surgery~* History of psychiatric disability judged by the investigator to potentially hamper compliance with the study protocol and follow-up schedule.~* Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- RIFRAM implant (Type: EXPERIMENTAL): RIFRAM implant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Breast Irradiation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven invasive breast carcinoma~* cT1-2N0 breast cancer~* cM0~* female patients ≤ 50 years~* planned breast conserving surgery~* ability to undergo irradiation and surgery~* signed written informed consent~Exclusion Criteria:~* prior surgery or radiotherapy for the protocol tumor (neoadjuvant chemotherapy or endocrine therapy is allowed)~* planned oncoplastic reduction mammoplasty~* cTis~* extensive calcifications on mammagram (Birads 3,4 or 5)~* cT3-4 and/or cN1-3 invasive carcinoma~* distant metastasis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- radiation (Type: OTHER): intervention: pre-operative breast irradiation of 21 fx of 2.2Gy and boost 2.66Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Novel Airway Device to Aid Endotracheal Intubations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~\* undergoing ambulatory surgery under general anesthesia~Exclusion Criteria:~* pregnant patients~* parturients with past 60 days,~* poorly controlled diabetic patient with neuropathy and HbA1c \> 9.0%, \*preexisting nausea and vomiting,~* intestinal obstruction~* acute alcohol toxicity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pneumaglide (Type: EXPERIMENTAL): After induction of anesthesia Pneumaglide device will be placed in the mouth of the pneumaglide assigned patients.
- non-pneumaglide (Type: NO_INTERVENTION): The patients in non-pneumaglide will not have Pneumaglide insertion prior to intubation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Support and Rehabilitation Protocol for Non Metastatic Breast Cancer Patients in Complete Remission After Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* breast cancer~* treatment including a chemotherapy~* in complete remission~* last treatment in the last 9 months before inclusion~* signed consent~Exclusion Criteria:~* metastatic disease~* relapse~* women enable to have physical activity~* heart disease or any pathology preventing physical activity

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- dietary and physical training (Type: EXPERIMENTAL): 12 days session of physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
- control (Type: NO_INTERVENTION): dietary counseling by a dietetician in the anticancer hospital

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 years of age~* Diagnosis of DLBCL as documented by medical records and with histology based on criteria established by the World Health Organization~  * subtyping is required for DLBCL~ * c-myc+ defined as presence of c-myc breaks by karyotype/FISH and/or IHC ≥ 40%; this includes double hits (with bcl-2 breaks found using cytogenetics/FISH) and/or double expressors (with bcl-2 protein expression ≥ 70% by IHC); increased copy number in itself is not considered positivity for c-myc~* No prior therapy for diagnosis of DLBCL with exception of steroids~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0- 2 (Appendix B)~* Life expectancy of at least 6 months~* No history of medication dependent diabetes mellitus~* No evidence of acute or chronic metabolic acidosis (baseline venous lactate ≤ 4)~Exclusion Criteria~* Patient already on any class of anti-diabetic medication including metformin, insulin analogues, sulfonylureas, thiazolidinediones (TZDs) and the incretin-based therapies or clear need for therapeutic intervention based on fasting blood glucose~* Known histological transformation from indolent non-Hodgkin Lymphoma (iNHL) or chronic lymphocytic leukemia (CLL) to an aggressive form of non-Hodgkin's lymphoma (NHL) (ie, Richter transformation)~* Burkitt and/or precursor lymphoblastic leukemia/lymphoma.~* Presence of known intermediate- or high-grade myelodysplastic syndrome~* History of an active of treated non-lymphoid malignancy within the last 3 years excluding basal cell and squamous cell skin cancers~* Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of start of study drug.~* Subjects who have currently active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver involvement with NHL or stable chronic liver disease per investigator assessment)~* Renal insufficiency with creatinine \> 1.5 x upper limit of normal (ULN) OR creatinine clearance of \< 45 ml/min as calculated by the Cockcroft-Gault method~* CNS or leptomeningeal involvement of lymphoma~* HIV positive~* Ongoing inflammatory bowel disease~* Ongoing alcohol or drug addiction~* Pregnancy or breastfeeding~* History of prior allogeneic bone marrow progenitor cell or solid organ transplantation -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm, open label (Type: EXPERIMENTAL): Metformin added to standard of care treatment for all patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Oral Desogestrel Prior to Insertion of the Etonogestrel Subdermal Implant Improve Continuation Rate at One Year?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Women age of 18 - 42 years~* Interested in the use of ESI~* Accepting to have 90 days pre-treatment with OD~* Signed informed consent~Exclusion criteria:~* Pregnancy~* Lactation,~* vaginal bleeding of unknown origin,~* wish to become pregnant,~* weight over 80 kg,~* history of deep vein thrombosis/Pulmanory embolism,~* hypertension,~* Diabetes or other metabolic diseases,~* coagulation disorders,~* severe hepatic disorder,~* history of breast/endometrial cancer,~* known hypersensitivity to study drug,~* current treatment with enzyme inducing drugs (e.g.: phenytoin, carbamazepine, phenobarbital, etc.)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: t

Study Arms:
- ESI (Implanon NXT® subdermal implant) (Type: ACTIVE_COMPARATOR): In this group, the implant was inserted immediately after thorough explanations of the potential side effects and possible adverse events
- DSG + ESI(Desogestrel +Implanon NXT® subdermal implant) (Type: EXPERIMENTAL): In this group, patients were given a 3 months' supply of 75µg of DSG to be started immediately after which insertion of an ESI was proposed. Similarly, explanations of the potential side effects and possible adverse events were presented to the patient before treatment initiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.~2. Male and Female subjects between 18 and 45 years~3. WRAT-4 Reading \[127\] standard score \> 85~4. Able to undergo neuroimaging data collection procedures. For MS Participants~5. Definite diagnosis of RRMS \[128\]~6. EDSS of 0 to 6.0~7. Adequate vision as as reported by the participant (with correction if applicable)~8. Clinically prescribed Tecfidera, Tysabri or Ocrevus therapy by treating neurologist, with first dose being within 3 months + 14 days from baseline visit~9. At baseline visit, concurrent medications to be kept constant over three months prior to data collection visits~10. No relapse or steroids in previous month~Exclusion Criteria:~1. Unable or unwilling to provide informed consent.~2. Beck Depression Inventory-Fast Screen (BDI-FS) \[129, 130\] score of 4 or more~3. Current alcohol or other substance use disorder~4. Primary psychiatric disorder that would adversely influence ability to participate~5. Other neurological condition associated with cognitive impairment (e.g., epilepsy, brain injury)~6. Other serious uncontrolled medical condition (e.g., cancer or acute myocardial infarction)~7. Learned English language after 12 years of age~8. For low absolute low lymphocyte count (ALC), USPI guidance will be utilized.~   For MS participants:~9. Lemtrada, Cladribine, Mitoxantrone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- MS Patients (Type: None): Definite diagnosis of RRMS
- Healthy Controls (Type: None): gender aged match healthy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~To be eligible, a participant is required to be or have:~* Consented to participate in the LTE and has successfully completed the placebo-controlled 24-week Study AV-101-002.~Key Exclusion Criteria:~Subjects meeting any of the following criteria:~* The Investigator believes that it would not be in the best interest of the subject to be included in the LTE e.g., for clinical or social reasons.~* Subjects who were not compliant with study medication in AV-101-002 as assessed by the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Crossover AV-101 10 mg (Type: EXPERIMENTAL): Participants who previously received placebo in AV-101-002 received AV-101 (imatinib) 10 milligrams (mg) administered twice daily (BID) via dry powder inhalation.
- Placebo Crossover AV-101 35 mg (Type: EXPERIMENTAL): Participants who previously received placebo in AV-101-002 received AV-101 (imatinib) 35 mg administered BID via dry powder inhalation.
- Placebo Crossover AV-101 70 mg (Type: EXPERIMENTAL): Participants who previously received placebo in AV-101-002 received AV-101 (imatinib) 70 mg administered BID via dry powder inhalation.
- Continuing AV-101 10 mg (Type: EXPERIMENTAL): Participants who previously received AV-101 10 mg in AV-101-002 received AV-101 (imatinib) 10 mg administered BID via dry powder inhalation.
- Continuing AV-101 35 mg (Type: EXPERIMENTAL): Participants who previously received AV-101 35 mg in AV-101-002 received AV-101 (imatinib) 35 mg administered BID via dry powder inhalation.
- Continuing AV-101 70 mg (Type: EXPERIMENTAL): Participants who previously received AV-101 70 mg in AV-101-002 received AV-101 (imatinib) 70 mg administered BID via dry powder inhalation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tetracaine Versus Lidocaine Gel for Anesthetic Effect and Comfort in Patients Undergoing LASIK

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy volunteers of age 18 years or greater~Exclusion Criteria:~* Previous reaction/allergy to the same drug class~* prior ocular surgery~* active facial injuries~* any active current ophthalmological disease~* history of diabetes~* any current non- Over The Counter pain medication~* inability to complete the questionnaire.~* Economically or educationally disadvantaged persons, Prisoners, or Children~* Patients with fluctuating or impaired decision-making capacity~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tetracaine R/Lidocaine L (Type: ACTIVE_COMPARATOR): Participant's Right or Left eye will receive 0.5% Tetracaine drop, at 10 minutes and 5 minutes, prior to LASIK.
- Tetracaine L/Lidocaine R (Type: ACTIVE_COMPARATOR): Participant's Right or Left eye will receive 2% lidocaine gel, at 10 minutes and 5 minutes, prior to LASIK.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of a Knee Brace When Combined With Viscosupplementation in the Treatment of Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Subjects, over the age of 18, with a diagnosis of knee osteoarthritis which is confirmed by radiographs.~* Radiographs will be obtained and patients with mild to moderate knee osteoarthritis will qualify a subject for enrollment.~* Subjects will also have a documented varus deformity.~Exclusion criteria:~* Subjects with severe arthritis as demonstrated by radiographs.~* In addition those subjects with a known or suspected joint infection and subjects who had undergone arthrocentesis and/or intra-articular injection within 3 months of the study will be excluded.~* Female patients who are pregnant or breast feeding will also be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Viscosupplementation injections (Type: OTHER): Control group will receive a series of three viscosupplementation injections into the affected knee
- Off-loading knee brace (Type: EXPERIMENTAL): None
- Viscosupplementation and knee brace (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues